BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Armuzzi A, Avedano L, Greveson K, Kang T. Nurses are Critical in Aiding Patients Transitioning to Biosimilars in Inflammatory Bowel Disease: Education and Communication Strategies. J Crohns Colitis 2019;13:259-66. [PMID: 30285235 DOI: 10.1093/ecco-jcc/jjy150] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Gasteiger C, den Broeder AA, Stewart S, Gasteiger N, Scholz U, Dalbeth N, Petrie KJ. The mode of delivery and content of communication strategies used in mandatory and non-mandatory biosimilar transitions: a systematic review with meta-analysis. Health Psychol Rev 2021;:1-21. [PMID: 34409923 DOI: 10.1080/17437199.2021.1970610] [Reference Citation Analysis]
2 Mazzoni D, Vener C, Mazzocco K, Monzani D, Pravettoni G. The Psychological Risks Associated With the Non-medical Switch From Biologics to Biosimilars. Front Psychol 2021;12:605643. [PMID: 33584474 DOI: 10.3389/fpsyg.2021.605643] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Vandenplas Y, Simoens S, Van Wilder P, Vulto AG, Huys I. Informing Patients about Biosimilar Medicines: The Role of European Patient Associations. Pharmaceuticals (Basel) 2021;14:117. [PMID: 33557030 DOI: 10.3390/ph14020117] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
4 D'Amico F, Solitano V, Peyrin-Biroulet L, Danese S. Nocebo effect and biosimilars in inflammatory bowel diseases: what's new and what's next? Expert Opin Biol Ther 2021;21:47-55. [PMID: 32857634 DOI: 10.1080/14712598.2020.1817374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Viscido A, Buda A, Caprioli F, Principi M, Daperno M, Armuzzi A. Use of biosimilars in inflammatory bowel diseases: A survey among the clinicians members of the Italian Group for the Study of Inflammatory Bowel Disease (IGIBD). Dig Liver Dis 2020;52:928-30. [PMID: 32616462 DOI: 10.1016/j.dld.2020.06.020] [Reference Citation Analysis]
6 Armuzzi A, Bouhnik Y, Cummings F, Bettey M, Pieper B, Kang T. Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice. Dig Liver Dis 2020;52:1259-65. [PMID: 32601035 DOI: 10.1016/j.dld.2020.06.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Haghnejad V, Le Berre C, Dominique Y, Zallot C, Guillemin F, Peyrin-biroulet L. Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease. Digestive and Liver Disease 2020;52:281-8. [DOI: 10.1016/j.dld.2019.09.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
8 Peyrin-biroulet L, Danese S, Cummings F, Atreya R, Greveson K, Pieper B, Kang T. Anti-TNF biosimilars in Crohn’s Disease: a patient-centric interdisciplinary approach. Expert Review of Gastroenterology & Hepatology 2019;13:731-8. [DOI: 10.1080/17474124.2019.1645595] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
9 Gecse KB, Cumming F, D’haens G. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients’ concerns? Expert Review of Gastroenterology & Hepatology 2018;13:143-55. [DOI: 10.1080/17474124.2019.1553617] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]